EMA Submission Translation: Navigating QRD Templates, MedDRA, and Linguistic Validation for EU Authorization

What EMA Submission Translation Actually Involves

Getting a pharmaceutical product approved in the European Union means more than submitting solid science. The European Medicines Agency (EMA) requires that every regulatory filing be available in all 24 official EU languages — and every language version must be accurate, consistent, and formatted to exacting standards. EMA submission translation is not a peripheral task; it sits at the intersection of regulatory compliance, patient safety, and market access.

For biopharma companies pursuing centralized authorization, the translation burden is substantial. Marketing Authorisation Applications (MAAs), Common Technical Documents (CTD), Summaries of Product Characteristics (SmPCs), Patient Information Leaflets (PILs), clinical trial protocols, and packaging labels all need to be translated, reviewed, and validated — often under tight deadlines with little room for error.

The Scope: Documents, Languages, and Timelines

Under the centralized procedure, a single submission may require translation into every official EU language. This is not optional — it is a regulatory prerequisite for obtaining marketing authorization that applies across all member states.

The documents that typically require translation include:

• Marketing Authorisation Applications and supporting dossiers
• SmPCs, PILs, and labeling/packaging text
• Clinical study reports and pharmacovigilance documentation
• Expert reports, validation protocols, and product quality data
• Patient-Reported Outcome (PRO) instruments and informed consent forms

Timelines are unforgiving. For translated documents submitted during the review cycle, companies may face deadlines as short as 20 days. At the End of Procedure (EoP) stage — after the EMA issues its opinion — marketing authorization holders can have as few as five calendar days to implement final amendments across all 24 language versions. Missing these windows means delays that directly affect product launch dates.

QRD Templates and Formatting: Precision Beyond Words

The EMA's Quality Review of Documents (QRD) group publishes templates that govern not just the content but the exact formatting of product information. SmPCs, PILs, and labeling must follow these templates down to the font, alignment, and indentation.

Specific QRD requirements include:

• Times New Roman, size 11, for body text
• Left-aligned text with 1 cm indentation for bullet points
• Headers and section wording that mirror the exact phrasing in national templates
• Consistent use of approved regulatory terminology throughout

Deviating from these formatting rules — even seemingly minor ones — can result in regulatory queries or outright rejection. The QRD templates are updated periodically, and using an outdated version is a common and costly mistake.

Terminology Standards: MedDRA, EDQM, and the "Drug" Problem

Terminology consistency is one of the most critical and most frequently mishandled aspects of EMA submission translation. Translators must use standardized medical and regulatory lexicons, chief among them the Medical Dictionary for Regulatory Activities (MedDRA) for adverse event terminology and EDQM Standard Terms for pharmaceutical substances.

A particularly instructive example: the EMA explicitly advises against using the word "drug" in product information annexes. In several EU member states, the term can be misinterpreted or carry connotations of illicit substances. The agency recommends using "medicinal product" or "medicine" instead, though the term remains acceptable in compound phrases like "adverse drug reaction."

This level of specificity extends across the entire submission. "False friends" — words that appear similar across languages but carry different meanings — are a constant risk when multiple translator teams work on different language versions without coordinated terminology management.

Linguistic Validation: Beyond Forward Translation

For Patient-Reported Outcomes and clinical research instruments, forward translation alone is insufficient. EMA expectations (aligned with FDA guidance in this area) require a full linguistic validation workflow:

1. Translatability assessment — evaluating source text for concepts that may not map cleanly across cultures
2. Forward translation by qualified, native-speaking translators with subject matter expertise
3. Back-translation by an independent team to verify accuracy
4. Harmonization across all language versions to ensure conceptual equivalence
5. Cognitive debriefing — pilot testing with native speakers from the target population
6. Review by native-speaking clinicians to confirm medical accuracy

This process is resource-intensive but essential. PRO instruments that have not been properly validated in the target language produce data that regulators may question — or reject entirely.

Common Mistakes That Derail EMA Submissions

Several recurring errors account for the majority of translation-related regulatory issues:

• Inconsistent terminology across documents or language versions, often caused by multiple translator teams working without shared glossaries
• Non-compliance with current QRD templates, including outdated formatting or section headers
• Overly literal translations that are technically accurate but unnatural, particularly problematic in PILs that patients must actually read and understand
• Lack of version control across the submission lifecycle, leading to discrepancies between source and translated documents
• Treating translation as a final-step task, which creates bottlenecks and compresses review cycles

The consequences range from regulatory queries that delay approval to outright rejection. In pharmacovigilance and post-approval changes, translation errors can pose direct risks to patient safety — incorrect dosage instructions or misunderstood contraindications in a PIL are not theoretical concerns.

Building a Translation Process That Holds Up Under Scrutiny

Regulatory inspections increasingly scrutinize the translation process itself. Companies must be able to produce documented evidence of how translations were created, including:

• Translator qualifications and certifications
• Review and approval workflows with named reviewers
• Reference materials and glossaries used
• Version control logs showing changes across iterations
• Back-translation and reconciliation records

ISO 17100 certification has become a baseline expectation for translation providers working on EMA submissions. But certification alone is not enough — the provider needs demonstrated expertise in life sciences, regulatory affairs, and the specific document types involved.

The most effective approach integrates translation planning into the dossier preparation timeline rather than treating it as a separate, downstream task. When translation starts earlier, terminology can be aligned across the program, reviewer feedback can be incorporated iteratively, and the final submission benefits from multiple quality gates instead of a single rushed review.

For organizations managing multiple products across the EU, maintaining a centralized terminology database and translation memory across submissions reduces rework and ensures consistency from one regulatory cycle to the next. This is particularly important for post-approval variations, where even small inconsistencies between the original submission and updated translations can trigger regulatory questions.

Where AI Translation Fits in the Regulatory Workflow

AI-powered translation tools are increasingly being adopted in regulatory workflows, but their role requires careful definition. For EMA submissions, AI translation works best as an acceleration layer within a human-controlled process — handling initial drafts, ensuring terminology consistency across large document sets, and supporting multilingual alignment of structured documents like SmPCs and labeling.

The key is maintaining the quality assurance architecture around the technology: expert review, back-translation verification, QRD template compliance checks, and full audit trails. When properly integrated, AI translation can help organizations meet the compressed timelines of centralized procedures without sacrificing the accuracy that regulators demand.

Tools that combine terminology management with translation capabilities are particularly valuable for regulatory teams. They allow subject matter experts to validate key terms once and apply that validation consistently across all language versions — reducing the risk of the terminology inconsistencies that are the most common source of translation-related regulatory queries. Platforms like ZettaLab's AI Translation Agent, designed specifically for biopharma regulatory workflows, offer terminology consistency, structural alignment, and enterprise-grade security features suited to IND, NDA, and BLA documentation — capabilities that map directly to the quality requirements of EMA multilingual submissions.

Conclusion

EMA submission translation is a specialized discipline with real consequences for approval timelines, patient safety, and commercial outcomes across the EU. The requirements are specific — QRD formatting, MedDRA terminology, linguistic validation for PROs, full audit trails — and the timelines leave little margin for error.

Companies that treat translation as a strategic part of the regulatory process, rather than an afterthought, are better positioned to navigate the centralized procedure efficiently. That means engaging specialized translators early, maintaining terminology discipline across the product lifecycle, and building quality gates that match the scrutiny the EMA applies to every language version of a submission.